osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'thanks']
7. #asco23 conclusion: adjuvant osimertinib has shown unprecedented, highly statistically significant, and clinically meaningful os benefit in patients with egfrm stage ib iiia nsclc. first in the world, thanks to adaura! #breakthrough 
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer